You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,001,489


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,001,489
Title:Method for constructing a novel affinity peptide library for binding immunoglobulin G based on a protein affinity model of protein A
Abstract: An affinity ligand peptide library of IgG constructed on the basis of Protein A affinity model and the application of a design method thereof. According to the Molecular Mechanics--Poisson-Boltzmann surface area (MM/PBSA) method and on the basis of the known human IgG-Protein A complex structure, the hot spots of Protein A that have high affinity for human IgG are obtained analytically, and a Protein A simplified affinity model is built thereof. An affinity peptide library of IgG is constructed including heptapeptide and octapeptide structural modes. On the basis of the peptide structural modes, the types of inserted amino acids that `X` residues represent are further identified using amino acid location method. Then, molecular docking and molecular dynamics simulation methods are used to screen the candidate peptides successively. Finally, the affinity peptide ligands that can effectively purify IgG are identified using affinity chromatography.
Inventor(s): Sun; Yan (Tianjin, CN), Zhao; Weiwei (Tianjin, CN), Liu; Fufeng (Tianjin, CN), Shi; Qinghong (Tianjin, CN)
Assignee: TIANJIN UNIVERSITY (Tianjin, CN)
Application Number:14/654,731
Patent Claims:1. A method for constructing a novel affinity ligand peptide library for binding immunoglobulin G on the basis of an affinity model of Protein A, comprising: adding a cysteine to a middle region of a peptide to obtain the following peptides: TABLE-US-00008 FYCHXXXE, FYXHCXXE, FYCHXXR, FYXHCXR, FYXCRXE, YFXCRXE, HXYFCXR, and HXYFCXK;

wherein `X` represents the common 19 amino acids except cysteine; and synthesizing one or more of the peptides.

2. The method of claim 1, wherein, the constructing is on the basis of six Staphylococal Protein A hot spots: F132, Y133, H137, E143, R146, and K154.

3. The method of claim 1, further comprising determining the kinds of amino acids `X` in the peptides that are within the scope of the peptide library using an amino acid location method.

4. The method of claim 3, wherein, a candidate peptide library is obtained and shown below: TABLE-US-00009 Peptide & Number of peptides Amino acids `X` represents FYCHX.sub.1X.sub.2X.sub.3E X.sub.1: A, R, N, D, Q, E, H, I, L, K, M, number: 990 T, W, Y, V X.sub.2: A, Q, E, I, L, K X.sub.3: A, R, D, Q, E, L, K, M, P, S, T FYX.sub.1HCX.sub.2X.sub.3E X.sub.1: A, R, N, D, I, P, T, W, Y number: 594 X.sub.2: A, Q, E, I, L, K X.sub.3: A, R, D, Q, E, L, K, M, P, S, T FYCHX.sub.1X.sub.2R X.sub.1: N, D, Q, E, H, I, K, M, F, P, T, number: 112 W, Y, V X.sub.2: Q, E, H, I, K, M, F, W FYX.sub.1HCX.sub.2R X.sub.1: A, R, N, D, I, P, T, W, Y number: 72 X.sub.2: Q, E, H, I, K, M, F, W FYX.sub.1CRX.sub.2E X.sub.1: A, R, N, D, Q, E, G, H, I, L, K, number: 153 M, F, P, W, Y, V X.sub.2: N, D, Q, E, L, M, S, T, W YFX.sub.1CRX.sub.2E X.sub.1: N, D, E, H, I, L, K, M,P, S, T, number: 117 Y, V X.sub.2: N, D, Q, E, L, M, S, T, W HX.sub.1YFCX.sub.2R X.sub.1: A, R, N, D, I, P, T, W, Y number: 54 X.sub.2: Q, H, K, S, W, Y HX.sub.1YFCX.sub.2K X.sub.1: A, R, N, D, I, P, T, W, Y number: 81 X.sub.2: A, R, Q, H, K, F, W, Y, V.

5. The method of claim 4, wherein the peptides in the candidate peptide library are screened by molecular docking, RMSD comparison, and rescreened by molecular dynamics simulation, obtaining peptide ligands possessing high affinity for human immunoglobulin G, which are SEQ ID NO: 1499, FYWHCLDE; SEQ ID NO: 1883, FYFCRWE; SEQ ID NO: 1309, FYIHCLPE; SEQ ID NO: 1576, FYYHCKKE; SEQ ID NO: 859, FYCHWALE; SEQ ID NO: 798, FYCHWQDE; SEQ ID NO: 757, FYCHTIDE; SEQ ID NO: 1073, FYRIICQRE; SEQ ID NO: 397, FYCHHKTE; SEQ ID NO: 606, FYCHLQKE; SEQ ID NO: 122, FYCHRKAE; SEQ ID NO: 147, FYCHNQDE; SEQ ID NO: 82, FYCHRQEE; and SEQ ID NO: 1133, FYNHCASE.

6. The method of claim 2, further comprising determining the kinds of amino acids `X` in the peptides that are within the scope of the peptide library using an amino acid location method.

7. The method of claim 6, wherein, a candidate peptide library is obtained and shown below: TABLE-US-00010 Peptide & Number of peptides Amino acids `X` represents FYCHX.sub.1X.sub.2X.sub.3E X.sub.1: A, R, N, D, Q, E, H, I, L, K, M, number: 990 T, W, Y, V X.sub.2: A, Q, E, I, L, K X.sub.3: A, R, D, Q, E, L, K, M, P, S, T FYX.sub.1HCX.sub.2X.sub.3E X.sub.1: A, R, N, D, I, P, T, W, Y number: 594 X.sub.2: A, Q, E, I, L, K X.sub.3: A, R, D, Q, E, L, K, M, P, S, T FYCHX.sub.1X.sub.2R X.sub.1: N, D, Q, E, H, I, K, M, F, P, T, number: 112 W, Y, V X.sub.2: Q, E, H, I, K, M, F, W FYX.sub.1HCX.sub.2R X.sub.1: A, R, N, D, I, P, T, W, Y number: 72 X.sub.2: Q, E, H, I, K, M, F, W FYX.sub.1CRX.sub.2E X.sub.1: A, R, N, D, Q, E, G, H, I, L, K, number: 153 M, F, P, W, Y, V X.sub.2: N, D, Q, E, L, M, S, T, W YFX.sub.1CRX.sub.2E X.sub.1: N, D, E, H, I, L, K, M,P, S, T, number: 117 Y, V X.sub.2: N, D, Q, E, L, M, S, T, W HX.sub.1YFCX.sub.2R X.sub.1: A, R, N, D, I, P, T, W, Y number: 54 X.sub.2: Q, H, K, S, W, Y HX.sub.1YFCX.sub.2K X.sub.1: A, R, N, D, I, P, T, W, Y number: 81 X.sub.2: A, R, Q, H, K, F, W, Y, V.

8. The method of claim 7, wherein, the peptides in the candidate peptide library are screened by molecular docking, RMSD comparison, and rescreened by molecular dynamics simulation, obtaining the top 14 peptide ligands possessing high affinity for human immunoglobulin G, which are SEQ ID NO: 1499, FYWHCLDE; SEQ ID NO: 1883, FYFCRWE; SEQ ID NO: 1309, FYIHCLPE; SEQ ID NO: 1576, FYYHCKKE; SEQ ID NO: 859, FYCHWALE; SEQ ID NO: 798, FYCHWQDE; SEQ ID NO: 757, FYCHTIDE; SEQ ID NO: 1073, FYRHCQRE; SEQ ID NO: 397, FYCHHKTE; SEQ ID NO: 606, FYCHLQKE; SEQ ID NO: 122, FYCHRKAE; SEQ ID NO: 147, FYCHNQDE; SEQ ID NO: 82, FYCHRQEE; and SEQ ID NO: 1133, FYNHCASE.

Details for Patent 10,001,489

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Csl Behring Ag CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN immune globulin intravenous (human) For Injection 102367 07/27/2000 ⤷  Try a Trial 2032-12-20
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 07/26/2007 ⤷  Try a Trial 2032-12-20
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 10/02/2009 ⤷  Try a Trial 2032-12-20
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 02/07/2013 ⤷  Try a Trial 2032-12-20
Bio Products Laboratory GAMMAPLEX immune globulin intravenous (human) Injection 125329 09/17/2009 ⤷  Try a Trial 2032-12-20
Bio Products Laboratory GAMMAPLEX immune globulin intravenous (human) Injection 125329 02/06/2017 ⤷  Try a Trial 2032-12-20
Csl Behring Ag HIZENTRA immune globulin subcutaneous (human), 20% liquid Injection 125350 03/04/2010 ⤷  Try a Trial 2032-12-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.